Related references
Note: Only part of the references are listed.First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with ImmuneCheckpoint Inhibitors
Olivier Bylicki et al.
BIODRUGS (2019)
Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
Narjust Duma et al.
MAYO CLINIC PROCEEDINGS (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
mTOR-mediated glycolysis contributes to the enhanced suppressive function of murine tumor-infiltrating monocytic myeloid-derived suppressor cells
Yuting Deng et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
The prognostic role of programmed cell death-ligand 1 expression in non-small cell lung cancer patients: An updated meta-analysis
Guangzhi Ma et al.
CLINICA CHIMICA ACTA (2018)
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F. McDermott et al.
NATURE MEDICINE (2018)
2-Deoxy-2-[fluorine-18] fluoro-D-glucose uptake on positron emission tomography is associated with programmed death ligand-1 expression in patients with pulmonary adenocarcinoma
Kyoichi Kaira et al.
EUROPEAN JOURNAL OF CANCER (2018)
PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data
Pedro N. Aguiar et al.
IMMUNOTHERAPY (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review
Robert Brody et al.
LUNG CANCER (2017)
PD-L1 IHC in NSCLC with a global and methodological perspective
Erik Thunnissen et al.
LUNG CANCER (2017)
Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on 18F-fluorodeoxyglucose positron emission tomography/computed tomography
Kazuki Takada et al.
CANCER MEDICINE (2017)
Resistance to PD1/PDL1 checkpoint inhibition
Jake S. O'Donnell et al.
CANCER TREATMENT REVIEWS (2017)
Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review
Peter M. Ellis et al.
CLINICAL LUNG CANCER (2017)
Therapeutic management options for stage III non-small cell lung cancer
Stephanie M. Yoon et al.
WORLD JOURNAL OF CLINICAL ONCOLOGY (2017)
Biomarkers associated with checkpoint inhibitors
G. Manson et al.
ANNALS OF ONCOLOGY (2016)
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
Justin F. Gainor et al.
CLINICAL CANCER RESEARCH (2016)
Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma
Marlon C. Rebelatto et al.
DIAGNOSTIC PATHOLOGY (2016)
Predictive Markers for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Lung Cancer
Takehito Shukuya et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer
Joseph McLaughlin et al.
JAMA ONCOLOGY (2016)
Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?
Mari Mino-Kenudson
CANCER BIOLOGY & MEDICINE (2016)
Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy
Xiangjiao Meng et al.
CANCER TREATMENT REVIEWS (2015)
Nutrient Competition: A New Axis of Tumor Immunosuppression
Madhusudhanan Sukumar et al.
CELL (2015)
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chih-Hao Chang et al.
CELL (2015)
Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart
William D. Travis et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells
Annie A. Wu et al.
ONCOIMMUNOLOGY (2015)
The Emerging Hallmarks of Metabolic Reprogramming and Immune Evasion: Distinct or Linked?
Irina Kareva et al.
CANCER RESEARCH (2013)
Share Paper
